Bachem Holding AG Stock Swiss Exchange
Equities
BANB
CH0012530207
Biotechnology & Medical Research
Sales 2024 * | 649M 714M | Sales 2025 * | 823M 906M | Capitalization | 5.89B 6.48B |
---|---|---|---|---|---|
Net income 2024 * | 127M 140M | Net income 2025 * | 160M 176M | EV / Sales 2024 * | 8.92 x |
Net cash position 2024 * | 104M 114M | Net Debt 2025 * | 58.76M 64.7M | EV / Sales 2025 * | 7.23 x |
P/E ratio 2024 * |
46.9
x | P/E ratio 2025 * |
36.5
x | Employees | 2,006 |
Yield 2024 * |
1.09% | Yield 2025 * |
1.15% | Free-Float | 94.31% |
Latest transcript on Bachem Holding AG
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 18-12-31 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 12-04-24 |
Director/Board Member | 51 | 11-04-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 18 M€ | +1.40% | - |
1st Jan change | Capi. | |
---|---|---|
-1.82% | 41.35B | |
+41.93% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |